China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Biogen Inc. (NASDAQ:BIIB), currently trading near its 52-week low at $156.19, finds itself at a critical juncture as it navigates the launch of its Alzheimer's treatment Leqembi while grappling with ...

Australia's corporate watchdog on Wednesday said it has sued trading platform Binance Australia Derivatives, alleging that ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.